ANGO icon

AngioDynamics

9.77 USD
+0.09
0.93%
Updated Aug 26, 10:41 AM EDT
1 day
0.93%
5 days
10.52%
1 month
7.13%
3 months
0.62%
6 months
1.66%
Year to date
8.80%
1 year
29.40%
5 years
7.84%
10 years
-33.94%
 

About: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Employees: 675

0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

64% more call options, than puts

Call options by funds: $364K | Put options by funds: $222K

10% more capital invested

Capital invested by funds: $332M [Q1] → $365M (+$33.1M) [Q2]

3.32% more ownership

Funds ownership: 87.14% [Q1] → 90.45% (+3.32%) [Q2]

2% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 53

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

4% less funds holding

Funds holding: 154 [Q1] → 148 (-6) [Q2]

14% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 21

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$16
64%
upside
Avg. target
$19
94%
upside
High target
$24
146%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Lake Street
Frank Takkinen
146%upside
$24
Buy
Initiated
16 Jul 2025
HC Wainwright & Co.
Yi Chen
64%upside
$16
Buy
Reiterated
16 Jul 2025
Canaccord Genuity
William Plovanic
74%upside
$17
Buy
Maintained
16 Jul 2025

Financial journalist opinion

Based on 4 articles about ANGO published over the past 30 days

Neutral
Zacks Investment Research
4 days ago
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
Positive
Seeking Alpha
1 week ago
AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul
AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results confirm an inflection point: MedTech sales grew 19.5% in FY25, adjusted EBITDA turned positive, and the company now boasts a strong net cash balance sheet. Favorable sector trends, regulatory wins, and unique product positioning (Auryon, AlphaVac, NanoKnife) underpin robust growth prospects and expanding addressable markets.
AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul
Neutral
Business Wire
2 weeks ago
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:0.
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
Neutral
Business Wire
4 weeks ago
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical.
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
Neutral
Business Wire
1 month ago
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate.
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
Neutral
Zacks Investment Research
1 month ago
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
Positive
The Motley Fool
1 month ago
Why AngioDynamics Stock Popped, Then Dropped Today
Tuesday started off well for AngioDynamics (ANGO -10.18%), maker of such medical devices as the NanoKnife tool for "electrocuting" cancer, as well as multiple devices for treating peripheral vascular disease. In the morning, AngioDynamics reported stronger-than-expected Q4 2025 sales and earnings, with sales of $80.2 million and an adjusted loss of $0.03 per share (instead of the $0.12-per-share forecast).
Why AngioDynamics Stock Popped, Then Dropped Today
Neutral
Seeking Alpha
1 month ago
AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET Company Participants James C. Clemmer - CEO, President & Director Stephen A.
AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript
Positive
Benzinga
1 month ago
AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting
AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the consensus for a per-share loss of 12 cents.
AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting
Neutral
The Motley Fool
1 month ago
AngioDynamics (ANGO) Q4 2025 Earnings Transcript
Image source: The Motley Fool.
AngioDynamics (ANGO) Q4 2025 Earnings Transcript
Charts implemented using Lightweight Charts™